Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair—A Systematic Review
| Autor: | Timothy D. Henry, Odayme Quesada, Balaj Rai, Janki Shukla |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty QH301-705.5 medicine.medical_treatment Ischemia Cell- and Tissue-Based Therapy Neovascularization Physiologic Antigens CD34 Review 030204 cardiovascular system & hematology Microcirculation Cell therapy Angina 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans ischemia with non-obstructive coronary arteries Biology (General) CD34 stem cell therapy Clinical Trials as Topic coronary microvascular dysfunction refractory angina business.industry Stem Cells Coronary flow reserve General Medicine Stem-cell therapy Canadian Cardiovascular Society medicine.disease Coronary arteries 030104 developmental biology medicine.anatomical_structure Microvessels Cardiology business Stem Cell Transplantation |
| Zdroj: | Cells, Vol 10, Iss 1137, p 1137 (2021) Cells |
| ISSN: | 2073-4409 0350-8609 |
| Popis: | Ischemia with non-obstructive coronary arteries (INOCA) is an increasingly recognized disease, with a prevalence of 3 to 4 million individuals, and is associated with a higher risk of morbidity, mortality, and a worse quality of life. Persistent angina in many patients with INOCA is due to coronary microvascular dysfunction (CMD), which can be difficult to diagnose and treat. A coronary flow reserve + cell therapy is a promising treatment option for these patients, as it has been shown to promote vascular repair and enhance angiogenesis in the microvasculature. The resulting restoration of the microcirculation improves myocardial tissue perfusion, resulting in the recovery of coronary microvascular function, as evidenced by an improvement in coronary flow reserve. A pilot study in INOCA patients with endothelial-independent CMD and persistent angina, treated with autologous intracoronary CD34+ stem cells, demonstrated a significant improvement in coronary flow reserve, angina frequency, Canadian Cardiovascular Society class, and quality of life (ESCaPE-CMD, NCT03508609). This work is being further evaluated in the ongoing FREEDOM (NCT04614467) placebo-controlled trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|